The new effort aims to stop the Hepatitis C virus in its tracks by increasing access to medications that can cure Hepatitis C and expanding programs to connect New Yorkers in high-risk communities with wrap-around Hepatitis C prevention, screenings and treatment services.
In 2014, NYC Council established the Viral Hepatitis Initiative, which has served to establish and sustain four programs to build community health organization capacity to prevent, identify, manage and treat hepatitis B and C.
The Hepatitis Clinical Training Program aims to increase the number of NYC clinicians who identify and and care for hepatitis B and C according to national guidelines
The Advisory Committee on Immunization Practices’ (ACIP) recommend HEPLISAV-B™ for use among individuals age 18 years and older to prevent hepatitis B infection (HBV).
The NYC Health Department recently released the 2018 version of City Health Information (CHI): Diagnosing & Managing Hep C providing guidance to Primary Care Providers in hepatitis C screening, management and treatment.
Sign on to a letter urging Congressional leaders to allocate opioid funding to CDC’s viral hepatitis program in FY2018.
Now is the time to submit your abstract to become part of the 2018 NYC Viral Hepatitis Research Symposium! The primary focus of the meeting is on addressing viral hepatitis in special populations. Authors are encouraged to submit abstracts on their research and health care evalua...
The NYC Health Department in collaboration with the Northeast/Caribbean AIDS Education and Training Center (AETC) Program hosted a symposium focusing on Eliminating Hep C in People Living with HIV in New York City.
The primary goals of the Manual are to increase advocates' knowledge about available HCV tests and treatments and to jumpstart discussions on advocacy strategies that can be used to open up affordable access for more people with HCV.
More than 60 organizations, including NVHR, signed onto a letter urging the Trump administration to invest in the Department of Health & Human Services Viral Hepatitis Action Plan
On October 16, 2014, the fee-for-service (FFS) pharmacy program implemented clinical criteria for Hepatitis C Virus (HCV) drug therapy, as was recommended by the Drug Utilization Review Board (DURB) at the September 18, 2014 meeting. Included in this criteria were the following ...